Louis Crenshaw, NP
Nurse Practitioner · Pineville, LANPI 1114994746
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 462 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. AbbVie accounts for 61.9% of it on its own, with 25 other manufacturers making up the rest. 2025 is the largest year on record at $1,775, 2.7 times the $647 reported in 2021. Among nurse practitioner clinicians in LA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 462 payments — averaging $14.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$4K
- Axsome Therapeutics, Inc.$572
- Otsuka America Pharmaceutical, Inc.$496
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$405
- Abbott$123
- Pfizer$122
- plus $912 from 20 others
What the payments were for
- Food & beverage$6,911100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 303 | $4,280 |
| Axsome Therapeutics, Inc. | 34 | $572 |
| Otsuka America Pharmaceutical, Inc. | 31 | $496 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 28 | $405 |
| Abbott | 6 | $123 |
| Pfizer | 7 | $122 |
| GSK | 6 | $108 |
| Corium, LLC | 7 | $100 |
| AstraZeneca | 5 | $84 |
| Biohaven Pharmaceuticals, Inc. | 5 | $77 |
| Alkermes, Inc. | 4 | $64 |
| Lilly USA, LLC | 3 | $61 |
| Novo Nordisk | 3 | $58 |
| Idorsia Pharmaceuticals US Inc | 3 | $52 |
| Amgen | 3 | $45 |
| Ardelyx, Inc. | 2 | $42 |
| Exact Sciences | 2 | $38 |
| Teva Pharmaceuticals USA, Inc. | 2 | $32 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $24 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $22 |
| Evofem Biosciences, Inc. | 1 | $21 |
| Lundbeck LLC | 1 | $18 |
| Neurocrine Biosciences, Inc. | 1 | $18 |
| Insulet Corporation | 1 | $17 |
| Novartis | 1 | $17 |
| Boehringer Ingelheim | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UBRELVY$134
How this compares
$6,911 in reported general payments places this provider in the 90th percentile of 969 nurse practitioner providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 50 | $62,953 |
| TrulicityDulaglutide | 37 | $47,020 |
| JardianceEmpagliflozin | 54 | $45,631 |
| OzempicSemaglutide | 36 | $44,938 |
| RexultiBrexpiprazole | 28 | $41,271 |
| EliquisApixaban | 35 | $25,121 |
| LinzessLinaclotide | 29 | $23,658 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 34 | $23,215 |
| XareltoRivaroxaban | 22 | $14,453 |
| AirsupraAlbuterol Sulfate/Budesonide | 27 | $12,522 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 21 | $11,613 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 22 | $10,440 |
| EntrestoSacubitril/Valsartan | 12 | $9,700 |
| Semglee (Yfgn) PenInsulin Glargine-Yfgn | 15 | $6,408 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 41 | $6,054 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $61 | $109,97387 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat | $15 | $57,24475 claims |
| Novo NordiskOzempic | $58 | $44,93836 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $496 | $41,27128 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $108 | $33,65556 claims |
| PfizerEliquis | $122 | $25,12135 claims |
| AbbVieLinzess, Synthroid | $4,280 | $24,42346 claims |
| AstraZenecaAirsupra, Symbicort | $84 | $17,55249 claims |
| NovartisEntresto | $17 | $9,70012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 969 nurse practitioner providers in Louisiana.
Other nurse practitioner in Pineville
- Karen DeshotelLafayette$264K
- Christopher ManuelKaplan$145K
- Tammy BennettShreveport$99K
- Jessica BordelonHammond$78K
- Matt LandryLafayette$50K
- Cynthia CobbLafayette$48K
- Ellen GentileWest Monroe$31K
- Reghan LittlepageAlexandria$24K
- April WoodrowOpelousas$24K
- Amanda EstapaHammond$21K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.